Theramx Inc.

Creating Value for the World


2022.01.18 : Segyebiz - Bio platform development company Theramx.Inc. promotes listing on KONEX
Writer 관리자 Date 2022.01.20 Hit 205
File file  file  


Theramx Corporation announced on the 18th that it would promote the listing on KONEX with the will to properly evaluate the company's value through listing on the occasion of the completion of the recent export of 'EG-Q' to Europe.


Theramx, which has a GMP production facility in Seongnam, Gyeonggi-do and its own research center in Uiwang, Gyeonggi-do, is focusing on developing a nano-bio material-based drug delivery (DDS) platform and a semiconductor-type diagnostic technology (Lab-on-a-Chip) platform. .


‘EG-Q’, which has obtained KFDA approval and European CE certification, is Spain in Europe. It is expected to be exported to the UK, France, China in Asia, Nigeria and South Africa in Africa, and Vietnam in Southeast Asia.


Based on solid technology and sales power based on these innovations, Theramx Co., Ltd. is preparing for a designated advisory contract with a large securities company to promote the listing on KONEX in the first half of this year. The company said.

Theramx Co., Ltd. was established after completing 9 domestic and international patent registrations and splitting from its parent company, Azothbio, an AI-based new drug development company.


An official said, "For the early commercialization of DDS system using nanofilm and semiconductor-type diagnostic technology, we actively utilize technological cooperation with the parent company, expand domestic demand and increase exports of 'EG-Q', and secure a stable portfolio. “I want to be properly evaluated for the company’s value in the market,” he said.


View article :